{"url_path":"/sec/halo/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-11","source_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000068-index.html","accession_number":"0001159036-26-000068","cik":"0001159036","ticker":"HALO","issuer_name":"HALOZYME THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000068-index.html","primary_entity_key":"0001159036","primary_entity_name":"HALOZYME THERAPEUTICS, INC."},"word_count":96,"has_tables":true,"body_markdown":"Item 2.Unregistered Sales of Equity Securities and Use of Proceeds\n\nIn February 2024, our Board of Directors authorized a new capital return program to repurchase up to $750.0 million of our outstanding common stock. There were no share repurchases made during the first quarter of 2026. As of March 31, 2026, $157.7 million of outstanding stock is available to be purchased under the program.\n\nIn May 2026, our Board of Directors authorized a new capital return program to repurchase up to $1 billion of our outstanding common stock by December 31, 2028.\n\n64\n\n[Table of Contents](#i66ba8166e9c94bfbbdc8e24cab8d4507_7)"}